Skip to main content
SpringerLink
Log in

MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Glioblastoma is a universally fatal cancer of the central nervous system which responds poorly to treatment. MGMT has potential as a predictive biomarker in glioblastoma patients to determine treatment response. However, methods of measuring MGMT are currently unsatisfactory, and as such, use of this marker has not translated well into the clinic. This paper aims to review current methodology of MGMT measurement, with a focus on immunohistochemistry as a potential way forward.

Topics and methods

Studies of glioma patients where MGMT immunohistochemistry was undertaken, as well as the literature surrounding methylation analyses and the regulation of MGMT, were reviewed.

Results

All methods of measuring MGMT were disputed in some way in the literature. A trend of discordance between methylation analyses and protein analyses was present. There is a lack of standardisation in the measurement of MGMT, and as a result, it seems that there are highly variable results.

Conclusions

No single method of MGMT analysis has emerged as a clear choice for routine clinical testing of MGMT in glioma patients. Although methylation analyses are favoured, their expense and inaccessibility are barriers to their use in routine clinical practice. More research into immunohistochemistry is needed to determine whether it can serve as a reliable and cost-effective alternative to methylation analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Anda T, Shabani HK, Tsunoda K, Tokunaga Y, Kaminogo M, Shibata S, Hayashi T, Iseki M (2003) Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 25(3):241–248

    Article  PubMed  CAS  Google Scholar 

  • Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. doi:10.1007/s00401-012-1016-2

    Google Scholar 

  • Balana C, Carrato C, Ramirez JL, Cardona AF, Berdiel M, Sanchez JJ, Taron M, Hostalot C, Musulen E, Ariza A, Rosell R (2011) Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. Clin Translat Oncol 13:677–685

    Article  CAS  Google Scholar 

  • Blough MD, Zlatescu MC, Cairncross JG (2007) O6-Methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 67(2):580–584. doi:10.1158/0008-5472.can-06-2782

    Article  PubMed  CAS  Google Scholar 

  • Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in Anaplastic Gliomas. Clin Cancer Res 11 (14):5167–5174. doi:10.1158/1078-0432.ccr-05-0230

    Google Scholar 

  • Brell M, Ibanez J, Tortosa A (2011) O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 11(1):35

    Article  PubMed  Google Scholar 

  • Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden: and should be considered when allocating research funds. Br J Cancer 92(2):241–245. doi:10.1038/sj.bjc.6602321

    PubMed  CAS  Google Scholar 

  • Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87(4):392–397. doi:10.1038/labinvest.3700520

    PubMed  CAS  Google Scholar 

  • Cao VT, Jung T-Y, Jung S, Jin S-G, Moon K-S, Kim I-Y, Kang S-S, Park C-S, Lee K-H, Chae H-J (2009) The correlation and prognostic significance of Mgmt promoter methylation and mgmt protein in glioblastomas. Neurosurgery 65 (5):866–875

    Google Scholar 

  • Capper D, Mittelbronn M, Meyermann R, Schittenhelm J (2008) Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 115(2):249–259. doi:10.1007/s00401-007-0310-x

    Article  PubMed  CAS  Google Scholar 

  • Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25(12):1470–1475

    Article  PubMed  CAS  Google Scholar 

  • Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE 7(3):13

    Article  Google Scholar 

  • Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350–1354. doi:10.1056/NEJM200011093431901

    Article  PubMed  CAS  Google Scholar 

  • Everhard S, Tost Jr, El Abdalaoui H, Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre J-Y, Thillet Jl (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro-Oncology 11 (4):348–356. doi:10.1215/15228517-2009-001

  • Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A (2010) Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. J Neurooncol 100(2):209–215. doi:10.1007/s11060-010-0163-3

    Article  PubMed  CAS  Google Scholar 

  • Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15(21):6683–6693

    Article  PubMed  CAS  Google Scholar 

  • Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121(11):2458–2464

    Article  PubMed  CAS  Google Scholar 

  • Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA (2009) Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 27(25):4155–4161. doi:10.1200/JCO.2008.21.6895

    Article  PubMed  CAS  Google Scholar 

  • Havik A, Brandal P, Honne H, Dahlback H-S, Scheie D, Hektoen M, Meling T, Helseth E, Heim S, Lothe R, Lind G (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Trans Med 10(1):36

    Article  Google Scholar 

  • Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi:10.1056/NEJMoa043331

    Article  PubMed  CAS  Google Scholar 

  • Jacinto FV, Esteller M (2007) MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 6(8):1155–1160

    Article  PubMed  CAS  Google Scholar 

  • Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87(10):1055–1065

    Article  PubMed  CAS  Google Scholar 

  • Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW (2011) O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE 6(2):e17156

    Article  PubMed  CAS  Google Scholar 

  • Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2):142–148. doi:10.1200/JCO.2010.30.2729

    Article  PubMed  CAS  Google Scholar 

  • Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T (2007) Novel mechanism whereby nuclear factor κB Mediates DNA damage repair through regulation of O6-methylguanine-DNA-methyltransferase. Cancer Res 67(18):8952–8959. doi:10.1158/0008-5472.can-06-3820

    Article  PubMed  CAS  Google Scholar 

  • Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS (2006) Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5(10):2531–2539. doi:10.1158/1535-7163.mct-06-0106

    Article  PubMed  CAS  Google Scholar 

  • Mellai M, Caldera V, Annovazzi L, Chio A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D (2009) MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genom Proteom 6(4):219–227

    CAS  Google Scholar 

  • Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115(20):4783–4794

    Article  PubMed  CAS  Google Scholar 

  • Middleton MR, Margison GP (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4(1):37–44

    Article  PubMed  CAS  Google Scholar 

  • Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Internat J Cancer 113(3):379–385. doi:10.1002/ijc.20575

    Article  Google Scholar 

  • Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T (2009) Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29(4):379–388. doi:10.1111/j.1440-1789.2008.00983.x

    Article  PubMed  Google Scholar 

  • Nakasu S, Fukami T, Baba K, Matsuda M (2004) Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70(3):333–340

    Article  PubMed  Google Scholar 

  • Ochsenbein AF, Schubert AD, Vassella E, Mariani L (2011) Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol 103(2):343–351

    Article  PubMed  CAS  Google Scholar 

  • Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T (2011) The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE 6(8):e23332

    Article  PubMed  CAS  Google Scholar 

  • Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87(1):71–78

    Article  PubMed  CAS  Google Scholar 

  • Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98(1):93–99. doi:10.1007/s11060-009-0067-2

    Article  PubMed  CAS  Google Scholar 

  • Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008a) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18(4):520–532

    PubMed  CAS  Google Scholar 

  • Preusser M, Elezi L, Hainfellner JA (2008b) Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 27(6):388–390

    PubMed  CAS  Google Scholar 

  • Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118(17):4201–4211

    Google Scholar 

  • Riemenschneider MJ, Hegi ME, Reifenberger G (2010) MGMT promoter methylation in malignant gliomas. Target Oncol 5(3):161–165

    Article  PubMed  Google Scholar 

  • Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O’Neill BP, James CD, Passe S, Slezak J, Giannini C (2008) MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16(1):59–65

    PubMed  CAS  Google Scholar 

  • Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tanaka S (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32(8):1220–1227

    Article  PubMed  Google Scholar 

  • Sciuscio D, Diserens AC, van Dommelen K, Martinet D, Jones G, Janzer RC, Pollo C, Hamou MF, Kaina B, Stupp R, Levivier M, Hegi ME (2011) Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res 17(2):255–266. doi:10.1158/1078-0432.CCR-10-1931

    Article  PubMed  CAS  Google Scholar 

  • Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K (2009) Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29(10):3759–3768

    PubMed  CAS  Google Scholar 

  • Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir 151(11):1349–1358

    Article  Google Scholar 

  • Spiegl-Kreinecker S, Pirker C, Filipits M, Latsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M, Fischer J, Berger W (2009) O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro-Oncol. doi:10.1093/neuonc/nop003

    PubMed  Google Scholar 

  • Srivenugopal KS, Shou J, Mullapudi SRS, Lang FF, Rao JS, Ali-Osman F (2001) Enforced expression of wild-type p53 curtails the transcription of the O6-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 7(5):1398–1409

    PubMed  CAS  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Jr Curschmann, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff R (2005a) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330

    Article  PubMed  CAS  Google Scholar 

  • Stupp R, van den Bent MJ, Hegi ME (2005b) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Reports 5(3):198–206

    Article  CAS  Google Scholar 

  • Stupp R, Bent MJVD, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi M, Perry JR, Picard M, Weller M (2010a) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, openlabel, controlled phase III trial (CENTRIC). J Clin Oncol 28:15s (suppl; abstr TPS152)

    Google Scholar 

  • Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010b) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712–2718. doi:10.1200/JCO.2009.26.6650

    Article  PubMed  CAS  Google Scholar 

  • Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK (2011) Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics 66(10):1747–1755

    Article  PubMed  Google Scholar 

  • Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V, Mariani L (2011) Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II–IV) of adults. J Neuro-oncol 104(1):293–303. doi:10.1007/s11060-010-0490-4

    Article  CAS  Google Scholar 

  • Vig HS, Wang C (2012) The evolution of personalized cancer genetic counseling in the era of personalized medicine. Fam Cancer. doi:10.1007/s10689-012-9524-8

    PubMed  Google Scholar 

  • Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bahr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W (2010) Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 77(3):670–676. doi:10.1016/j.ijrobp.2009.05.031

    Article  PubMed  CAS  Google Scholar 

  • Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1):39–51

    Article  PubMed  CAS  Google Scholar 

  • Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 67(1):1–15

    Article  PubMed  CAS  Google Scholar 

  • Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H (2009) Promoter methylation and polymorphisms of the <i>MGMT</i>gene in glioblastomas: a population-based study. Neuroepidemiology 32(1):21–29

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the ongoing support of the Cure for Life Foundation. Dr Kerrie McDonald is a recipient of the Cancer Institute NSW Career Development Fellowship. We would also like to thank Dr Janice Brewer, a neuropathologist from the Department of Anatomical Pathology, Royal North Shore Hospital, NSW, for the MGMT IHC photographs.

Conflict of interest

We declare that there is no conflict of interest in this paper.

Author information

Authors and Affiliations

  1. Cure for Life Foundation for Neuro-Oncology, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Kensington, Australia

    Sofia Mason & Kerrie McDonald

Authors
  1. Sofia Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerrie McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sofia Mason.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mason, S., McDonald, K. MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry. J Cancer Res Clin Oncol 138, 1789–1797 (2012). https://doi.org/10.1007/s00432-012-1312-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-012-1312-1

Keywords

Search

Navigation